High-tech hash in a vapourizer

Britain’s GW Pharmaceuticals has begun clinical trials for their new medical cannabis inhaler. The device will be tested for three years by 900 patients with ailments such as glaucoma, multiple sclerosis and neuralagia. The cannabis is in the form of a brown, viscuous liquid which is heated in a laboratory oven then placed into the inhaler, where the vapours can be sucked up through a tube by the patient. There are plans to incorporate the heating mechanism into the inhaler for more portable use.